U.S. markets close in 5 hours 46 minutes

Karuna Therapeutics, Inc. (KRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
115.02+1.60 (+1.42%)
As of 10:08AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close113.41
Open113.41
Bid114.37 x 1300
Ask115.61 x 800
Day's Range112.08 - 115.07
52 Week Range69.58 - 146.97
Volume27,639
Avg. Volume173,225
Market Cap3.388B
Beta (5Y Monthly)1.81
PE Ratio (TTM)N/A
EPS (TTM)-3.36
Earnings DateAug 03, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est160.31
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Hedge Funds Are Crazy About Karuna Therapeutics, Inc. (KRTX)
    Insider Monkey

    Hedge Funds Are Crazy About Karuna Therapeutics, Inc. (KRTX)

    As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the fourth quarter of 2019. A significant number of hedge funds continued their strong […]

  • Cerevel Test Data Scrambles Schizophrenia Stocks
    Barrons.com

    Cerevel Test Data Scrambles Schizophrenia Stocks

    The biotech's stock soared on Tuesday, before management said it would sell more equity, while a company developing a rival schizophrenia drug fell.

  • Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers
    Business Wire

    Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers

    BOSTON, June 23, 2021--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced data from its completed Phase 1b trial evaluating the safety and tolerability of KarXT (xanomeline-trospium) in healthy elderly volunteers. The Company had previously announced a preliminary analysis of data from the first two cohorts in the trial earlier th